0001193125-22-098074.txt : 20220407 0001193125-22-098074.hdr.sgml : 20220407 20220407061802 ACCESSION NUMBER: 0001193125-22-098074 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20220406 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220407 DATE AS OF CHANGE: 20220407 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SELECTA BIOSCIENCES INC CENTRAL INDEX KEY: 0001453687 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37798 FILM NUMBER: 22812241 BUSINESS ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-923-1400 MAIL ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 8-K 1 d535347d8k.htm 8-K 8-K
SELECTA BIOSCIENCES INC false 0001453687 0001453687 2022-04-06 2022-04-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 6, 2022

 

 

SELECTA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37798   26-1622110
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

65 Grove Street, Watertown, MA 02472

(Address of principal executive offices) (Zip Code)

(617) 923-1400

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.0001 par value per share   SELB   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 1.01

Entry Into a Material Definitive Agreement

On April 6, 2022, Selecta Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with SVB Securities LLC (the “Representative”), as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 27,428,572 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants (the “Warrants”, and together with the Shares, the “Securities”) to purchase up to 20,571,429 shares of Common Stock. All of the Securities are being sold by the Company. Each Share and accompanying Warrant to purchase 0.75 shares of Common Stock is being sold at a combined offering price of $1.41. The Company expects to receive net proceeds from the Offering of approximately $36.0 million, after deducting underwriting discounts and commissions and estimated offering expenses.

The Offering was made, and the Securities will be issued, pursuant to the Company’s registration statement on Form S-3 (File No. 333-241692), which was filed with the Securities and Exchange Commission on August 6, 2020 and declared effective on August 14, 2020, a base prospectus dated August 14, 2020 and the related prospectus supplement dated April 6, 2022. The Offering is expected to close on or about April 11, 2022, subject to customary closing conditions.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Underwriting Agreement. Each of the Company’s directors and executive officers has agreed, subject to certain exceptions, not to sell or transfer any Common Stock for 90 days, and the Company has agreed, subject to certain exceptions, not to sell or transfer any Common Stock for 90 days, in each case, without first obtaining the written consent of the Representative.

The foregoing description of the terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 hereto and incorporated by reference herein.

The Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock and also upon any distributions for no consideration of assets to the Company’s stockholders. Each Warrant is exercisable at any time and from time to time after issuance. In the event of certain corporate transactions, the holders of the Warrants will be entitled to receive, upon exercise of the Warrants, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Warrants immediately prior to such transaction. The Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which holders of Common Stock are entitled. The foregoing summary of the Warrants does not purport to be complete and is subject to, and qualified in its entirety by, the form of Warrant, which is filed herewith as Exhibit 4.1 and incorporated herein by reference.

A copy of the opinion of Covington & Burling LLP relating to the validity of the Securities sold in the Offering and the shares of Common Stock issuable upon exercise of the Warrants is attached as Exhibit 5.1 hereto.

 

Item 8.01

Other Events

On April 6, 2022, the Company issued a press release announcing the pricing of the Offering. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Forward-Looking Statements

This Current Report contains forward-looking statements. All statements other than statements of historical facts contained in this Current Report may be forward-looking statements. Such statements include, but are not limited to the Company’s contemplated issuance of securities, the amount of proceeds from the Offering and the closing of the Offering. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “expects,” “plans,” “intends,” “believes” or “estimates” or the negative of these terms or other similar expressions. Forward-looking statements involve known and


unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For example, there are risks associated with the underwriters fulfilling their obligations to purchase the Securities and the Company’s ability to satisfy its conditions to close the Offering. Risk factors that may cause actual results to differ are discussed in the Company’s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q. All forward-looking statements are qualified in their entirety by this cautionary statement. The Company is providing this information as of the date of this Current Report and does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 

Item 9.01

Financial Statements and Exhibits.

 

  (d)

Exhibits.

 

EXHIBIT
NUMBER
   EXHIBIT DESCRIPTION
1.1    Underwriting Agreement, dated April 6, 2022, by and between Selecta Biosciences, Inc. and SVB Securities LLC, as representative of the several underwriters named therein.
4.1    Form of Warrant
5.1    Opinion of Covington & Burling LLP
23.1    Consent of Covington & Burling LLP (included in Exhibit 5.1)
99.1    Press Release of Selecta Biosciences, Inc. dated April 6, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SELECTA BIOSCIENCES, INC.  
Date: April 7, 2022     By:  

/s/ Carsten Brunn, Ph.D.

 
      Carsten Brunn, Ph.D.  
      President and Chief Executive Officer  
EX-1.1 2 d535347dex11.htm EX-1.1 EX-1.1

Exhibit 1.1

SELECTA BIOSCIENCES, INC.

(a Delaware corporation)

27,428,572 Shares of Common Stock

and

Warrants to Purchase 20,571,429 Shares of Common Stock

UNDERWRITING AGREEMENT

April 6, 2022

SVB Securities LLC

as Representative of the several Underwriters

c/o SVB Securities LLC

53 State Street, 40th Floor

Boston, MA 02109

Ladies and Gentlemen:

Selecta Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement with SVB Securities LLC (“SVB Securities”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for which SVB Securities is acting as representative (in such capacity, the “Representative”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of an aggregate of 27,428,572 shares of common stock (the “Shares”), par value $0.0001 per share, of the Company (“Common Stock”) and (ii) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of warrants to purchase 20,571,429 shares of Common Stock (the “Warrants”). The Shares and the Warrants are herein called, collectively, the “Securities.” The shares of Common Stock issuable upon exercise of the Warrants are herein referred to as the “Warrant Shares”.

The Company understands that the Underwriters propose to make an offering of the Securities as soon as the Representative deems advisable after this Underwriting Agreement (this “Agreement”) has been executed and delivered.

The Company has filed with the Securities and Exchange Commission (the “Commission”) a shelf registration statement on Form S-3 (No. 333-241692) covering the offering and sale of certain securities, including the Securities, under the Securities Act of 1933, as amended (the “1933 Act”) and the rules and regulations of the Commission promulgated thereunder (the “1933 Act Regulations”), which shelf registration statement was declared effective on August 14, 2020. Such registration statement, as of any time, means such registration statement as amended by any post-effective amendments thereto to such time, including the exhibits and any schedules thereto at such time, the documents incorporated or deemed to be incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the


documents otherwise deemed to be a part thereof as of such time pursuant to Rule 430B under the 1933 Act Regulations (“Rule 430B”), is referred to herein as the “Registration Statement;” provided, however, that the “Registration Statement” without reference to a time means such registration statement as amended by any post-effective amendments thereto as of the time of the first contract of sale for the Securities, which time shall be considered the “new effective date” of such registration statement with respect to the Securities within the meaning of paragraph (f)(2) of Rule 430B, including the exhibits and schedules thereto as of such time, the documents incorporated or deemed incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as of such time pursuant to the Rule 430B. Any registration statement filed pursuant to Rule 462(b) of the 1933 Act Regulations is herein called the “Rule 462(b) Registration Statement” and, after such filing, the term “Registration Statement” shall include the Rule 462(b) Registration Statement. Each preliminary prospectus used in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to herein as a “preliminary prospectus.” Promptly after execution and delivery of this Agreement, the Company will prepare and file a final prospectus relating to the Securities in accordance with the provisions of Rule 424(b) under the 1933 Act Regulations (“Rule 424(b)”). The final prospectus, in the form first furnished or made available to the Underwriters for use in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to herein as the “Prospectus.” For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (or any successor system) (“EDGAR”).

As used in this Agreement:

“Applicable Time” means 6:00 p.m., New York City time, on April 6, 2022 or such other time as agreed by the Company and the Representative.

“General Disclosure Package” means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus (including any documents incorporated therein by reference) that is distributed to investors prior to the Applicable Time and the information included on Schedule B-1 hereto, all considered together.

“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the 1933 Act Regulations (“Rule 433”), including without limitation any “free writing prospectus” (as defined in Rule 405 of the 1933 Act Regulations (“Rule 405”)) relating to the Securities that is (i) required to be filed with the Commission by the Company, (ii) a “road show for an offering that is a written communication” within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g).

“Issuer General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors (other than a “bona fide electronic road show,” as defined in Rule 433 (a “Bona Fide Electronic Road Show”)), as evidenced by its being specified in Schedule B-2 hereto.

 

2


“Issuer Limited Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.

“Testing-the-Waters Communication” means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the 1933 Act.

“Written Testing-the-Waters Communication” means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the 1933 Act.

All references in this Agreement to financial statements and schedules and other information which is “contained,” “included” or “stated” (or other references of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include all such financial statements and schedules and other information incorporated or deemed incorporated by reference in the Registration Statement, any preliminary prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and all references in this Agreement to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the “1934 Act”), incorporated or deemed to be incorporated by reference in the Registration Statement, such preliminary prospectus or the Prospectus, as the case may be, at or after the execution and delivery of this Agreement.

SECTION 1. Representations and Warranties.

(a) Representations and Warranties by the Company. The Company represents and warrants to each Underwriter as of the date hereof, the Applicable Time and the Closing Time (as defined below), and agrees with each Underwriter, as follows:

(i) Registration Statement and Prospectuses. The Company meets the requirements for use of Form S-3 under the 1933 Act. Each of the Registration Statement and any amendment thereto has become effective under the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued by the Commission under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued by the Commission and no proceedings for any of those purposes have been instituted by the Commission or are pending or, to the Company’s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information.

Each of the Registration Statement and any post-effective amendment thereto, at the time of its effectiveness and at each deemed effective date with respect to the Underwriters pursuant to Rule 430B(f)(2) under the 1933 Act Regulations, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus delivered to the Underwriters for use in connection with the offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the Prospectus, when they became effective or at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the 1934 Act and the rules and regulations of the Commission under the 1934 Act (the “1934 Act Regulations”).

 

 

3


The Registration Statement, any preliminary prospectus and the Prospectus, and the filing of the Registration Statement, any preliminary prospectus and the Prospectus with the Commission have been duly authorized by and on behalf of the Company, and the Registration Statement has been duly executed pursuant to such authorization.

(ii) Accurate Disclosure. Neither the Registration Statement nor any amendment thereto, at its effective time or at the Closing Time, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, none of (A) the General Disclosure Package, (B) any individual Issuer Limited Use Free Writing Prospectus, when considered together with the General Disclosure Package, nor (C) any individual Written Testing-the-Waters Communication, when considered together with the General Disclosure Package, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), or at the Closing Time, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, at the time the Registration Statement became effective or when such documents incorporated by reference were filed with the Commission, as the case may be, when read together with the other information in the Registration Statement, the General Disclosure Package or the Prospectus, as the case may be, did not and will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

The representations and warranties in this subsection shall not apply to statements in or omissions from the Registration Statement (or any amendment thereto), the General Disclosure Package or the Prospectus (or any amendment or supplement thereto, including any prospectus wrapper) made in reliance upon and in conformity with written information furnished to the Company by any Underwriter through the Representative expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the information in first sentence of the fifth paragraph and the eleventh paragraph under the caption “Underwriting” contained in the Prospectus (collectively, the “Underwriter Information”).

(iii) Issuer Free Writing Prospectuses. No Issuer Free Writing Prospectus conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein, and any preliminary or other prospectus deemed to be a part thereof that has not been superseded or modified. No filing of any “road show” (as defined in Rule 433(h)) is required in connection with the offering of the Securities. Any Issuer Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the 1933 Act has been, or will be, filed with the Commission in accordance with the requirements of the 1933 Act and the 1933 Act Regulations. Each Issuer Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the 1933 Act or that was prepared by or behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Except for the Issuer Free Writing Prospectuses, if any, identified in Schedule B-2 hereto, and electronic road shows, if any, each furnished to the Representative before first use, the Company has not prepared, used or referred to, and will not, without the prior consent of the Representative, prepare, use or refer to, any issuer free writing prospectus.

 

4


(iv) Testing-the-Waters Materials. The Company (A) has not engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the consent of the Representative with entities that are qualified institutional buyers within the meaning of Rule 144A under the 1933 Act or institutions that are accredited investors within the meaning of Rule 501 under the 1933 Act and (B) has not authorized anyone other than the Representative to engage in Testing-the-Waters Communications. The Company reconfirms that the Representative has been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not distributed any Written Testing-the-Waters Communications other than those listed on Schedule B-3 hereto.

(v) Company Not Ineligible Issuer. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the 1933 Act Regulations) of the Securities and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.

(vi) The Agreement. This Agreement has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable law and except as the enforcement hereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles.

(vii) Capitalization. The Company has an authorized and outstanding capitalization as set forth in the section of the Registration Statement, the General Disclosure Package and the Prospectus entitled “Description of Capital Stock” (subject to the issuance of Common Shares upon exercise of stock options and warrants disclosed as outstanding in the Registration Statement, the General Disclosure Package and the Prospectus and the grant of options under existing stock option plans described in the Registration Statement, the General Disclosure Package and the Prospectus); all of the issued and outstanding shares of capital stock of the Company, including the Common Shares, have been duly authorized and validly issued and are fully paid and non-assessable, have been issued in compliance with all applicable securities laws and were not issued in violation of any preemptive right, resale right, right of first refusal or similar right.

(viii) Good Standing of Company. The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the State of Delaware, with full corporate power and authority to own, lease and operate its properties and conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus, and to execute and deliver this Agreement and to issue, sell and deliver the Securities as contemplated herein.

 

5


(ix) Foreign Qualification of Company. The Company is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction where the ownership or leasing of its properties or the conduct of its business requires such qualification, except where the failure to be so qualified and in good standing would not, individually or in the aggregate, either (i) have a material adverse effect on the business, properties, financial condition, results of operations or prospects related thereto of the Company and the Subsidiaries taken as a whole, (ii) prevent or materially interfere with the consummation of the transactions contemplated hereby or (iii) result in the delisting of the Common Shares from the Nasdaq Global Market (the occurrence of any such effect or any such prevention or interference or any such result described in the foregoing clauses (i), (ii) or (iii) being herein referred to as a “Material Adverse Effect”).

(x) Good Standing and Foreign Qualification of Subsidiaries. The Company has no subsidiaries (as defined under the 1933 Act) other than the subsidiaries most recently disclosed in its filings available on EDGAR (collectively, the “Subsidiaries”); the Company owns all of the issued and outstanding membership interests or capital stock of each of the Subsidiaries; other than the membership interests or capital stock of the Subsidiaries, the Company does not own, directly or indirectly, any shares of stock or any other equity interests or long-term debt securities of any corporation, firm, partnership, joint venture, association or other entity; complete and correct copies of the charters and the bylaws or similar governing documents of the Company and each Subsidiary and all amendments thereto have been delivered to you (including by being made available to you through EDGAR), and no changes therein will be made on or after the date hereof through and including the time of any time of purchase; each Subsidiary has been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, with full limited liability company or corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus; each Subsidiary is duly qualified to do business as a foreign limited liability company or corporation and is in good standing in each jurisdiction where the ownership or leasing of its properties or the conduct of its business requires such qualification, except where the failure to be so qualified and in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; all of the outstanding membership interests or shares of capital stock of each of the Subsidiaries have been duly authorized and validly issued, are fully paid and non-assessable, have been issued in compliance with all applicable securities laws, were not issued in violation of any preemptive right, resale right, right of first refusal or similar right and are owned by the Company subject to no security interest, other encumbrance or adverse claims; no options, warrants or other rights to purchase, agreements or other obligations to issue or other rights to convert any obligation into shares of capital stock or ownership interests in the Subsidiaries are outstanding; and each “significant subsidiary” of the Company, as that term is defined in Rule 1-02(w) of Regulation S-X under the 1933 Act, is listed in Exhibit 21.1 to the Company’s most recent Annual Report on Form 10-K (or otherwise in a subsequent filing available on EDGAR).

(xi) Authorization of the Securities. The Shares have been duly and validly authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued, fully paid and non-assessable and free of statutory and contractual preemptive rights, resale rights, rights of first refusal and similar rights, except for any such rights that have been waived; the Shares, when issued and delivered against payment therefor as provided herein, will be free of any restriction upon the voting or transfer thereof pursuant to the Delaware General Corporation Law or the Company’s charter and bylaws, each as amended to date and in the form filed as an exhibit to the Registration Statement, and any agreement or other instrument to which the Company is a party, except for any such rights that have been waived. The Warrants have been duly authorized for issuance by the Company. The Warrants, when executed and delivered by the Company pursuant to this Agreement, will be valid and binding agreements of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof

 

6


may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles. The Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the Warrants in a number sufficient to meet the current exercise requirements and, when issued and delivered upon exercise of the Warrants in accordance therewith, will be duly and validly issued, fully paid and nonassessable; and the issuance of the Warrant Shares is not subject to any preemptive or similar rights.

(xii) Description of Capital Stock. The capital stock of the Company, including the Securities, conforms in all material respects to each description thereof, if any, contained or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus.

(xiii) Non-Contravention. Neither the Company nor any of the Subsidiaries is in breach or violation of or in default under (nor has any event occurred which, with notice, lapse of time or both, would reasonably be expected to result in any breach or violation of, constitute a default under or give the holder of any indebtedness (or a person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a part of such indebtedness under) (A) its charter or bylaws or similar governing documents, or (B) any indenture, mortgage, deed of trust, bank loan or credit agreement or other evidence of indebtedness, or any material license, lease, contract or other agreement or instrument to which it is a party or by which it or any of its properties may be bound or affected, or (C) any U.S. or Russian federal, state, local or foreign law, regulation or rule, or (D) any rule or regulation of any self-regulatory organization or other non-governmental regulatory authority having jurisdiction over the Company or the Subsidiaries (including, without limitation, the rules and regulations of the Nasdaq Global Market), or (E) any decree, judgment or order applicable to it or any of its properties, except in the case of the foregoing clauses (B), (C), (D) and (E), for any such breaches, violations, defaults or events that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; The execution, delivery and performance of this Agreement, the issuance and sale of the Securities and the consummation of the transactions contemplated hereby will not conflict with, result in any breach or violation of or constitute a default under (nor constitute any event which, with notice, lapse of time or both, would reasonably be expected to result in any breach or violation of, constitute a default under or give the holder of any indebtedness (or a person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a part of such indebtedness under) (or result in the creation or imposition of a lien, charge or encumbrance on any property or assets of the Company or any Subsidiary pursuant to) (A) the charter or bylaws of the Company or similar organizational documents of any of the Subsidiaries, or (B) any indenture, mortgage, deed of trust, bank loan or credit agreement or other evidence of indebtedness, or any license, lease, contract or other agreement or instrument to which the Company or any of the Subsidiaries is a party or by which any of them or any of their respective properties is subject, or (C) any U.S. or Russian federal, state, local or foreign law, regulation or rule, or (D) any rule or regulation of any self-regulatory organization or other non-governmental regulatory authority having jurisdiction over the Company or the Securities (including, without limitation, the rules and regulations of the Nasdaq Global Market), or (E) any decree, judgment or order applicable to the Company or any of the Subsidiaries or any of their respective properties, except in the case of the foregoing clauses (B), (C), (D) and (E), for any such breaches, violations, defaults, repurchases, redemptions, repayments or events that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

7


(xiv) No Further Authorizations or Approvals Required. No approval, authorization, consent or order of or filing with any federal, state, local or foreign governmental or regulatory commission, board, body, authority or agency, or of or with any self-regulatory organization or other non-governmental regulatory authority (including, without limitation, the Nasdaq Global Market), or approval of the stockholders of the Company is required in connection with the issuance and sale of the Securities or the consummation by the Company of the transactions contemplated hereby, other than (i) the registration of the Securities under the 1933 Act, which has been effected (or, with respect to any registration statement to be filed hereunder pursuant to Rule 462(b) under the 1933 Act, will be effected in accordance herewith), (ii) any necessary qualification under the securities or blue sky laws of the various jurisdictions in which the Securities are being offered by the Underwriters, (iii) under the Conduct Rules of Financial Industry Regulatory Authority, Inc. (“FINRA”), (iv) any listing applications and related consents or any notices required by the Nasdaq Global Market in the ordinary course of the offering of the Securities or (v) filings with the Commission pursuant to Rule 424(b) under the 1933 Act, except as have already been made, obtained or waived or where the failure to obtain any such approval, authorization, consent, order or filing would not impair the ability of the Company to issue and sell the Securities or to consummate the transactions contemplated by this Agreement.

(xv) No Preemptive or Similar Rights. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus or as otherwise have been waived (i) no person has the right, contractual or otherwise, to cause the Company to issue or sell to it any Common Shares or shares of any other capital stock or other equity interests of the Company, (ii) no person has any preemptive rights, resale rights, rights of first refusal or other rights to purchase any Common Shares or shares of any other capital stock of or other equity interests in the Company and (iii) no person has the right to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of the Securities; no person has the right, contractual or otherwise, to cause the Company to register under the 1933 Act any Common Shares or shares of any other capital stock of or other equity interests in the Company or to include any such shares or interests in the Registration Statement or the offering contemplated thereby other than those that have been otherwise waived.

(xvi) Regulatory Compliance. Except for licenses, authorizations, consents and approvals required to be obtained from the Food and Drug Administration of the U.S. Department of Health and Human Services, each of the Company and the Subsidiaries has obtained all necessary licenses, authorizations, consents and approvals from all applicable authorities, in each case, as required to conduct their respective businesses as currently conducted, except where the failure to obtain such license, authorization, consent or approval or make such filing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; neither the Company nor any of the Subsidiaries is in violation of, or in default under, or has received written notice of any proceedings from any applicable governmental or regulatory authority relating to the revocation or adverse modification of, any such license, authorization, consent or approval, except as described in the Registration Statement and the Prospectus or where such violation, default, revocation or adverse modification would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

8


(xvii) Disclosure of Proceedings. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, there is no legal, governmental, administrative or regulatory investigation, action, suit, claim or proceeding pending or, to the Company’s knowledge, threatened to which the Company or any of its Subsidiaries or any of their respective officers or directors is a party (in their respective capacities as such), or to which any property of the Company or the Subsidiaries is or would reasonably be expected to be subject, before any court, board, body, regulatory or non-regulatory administrative agency or competent authority, which if determined adversely to the Company or any of the Subsidiaries would, individually or in the aggregate, have a Material Adverse Effect.

(xviii) Independent Accountants. Ernst & Young LLP, whose report on the consolidated financial statements of the Company and the Subsidiaries is included in the Registration Statement, the General Disclosure Package and the Prospectus, are independent registered public accountants as required by the 1933 Act and the rules of the Public Company Accounting Oversight Board.

(xix) Financial Statements. The financial statements included in the Registration Statement, the General Disclosure Package and the Prospectus, together with the related notes and schedules present fairly, in all material respects, the consolidated financial position of the Company and the Subsidiaries as of the dates indicated and the consolidated results of operations, cash flows and changes in stockholders’ equity of the Company and the Subsidiaries for the periods specified, and have been prepared in material compliance with the requirements of the 1933 Act and the 1934 Act and in conformity with United States generally accepted accounting principles (“GAAP”) applied on a consistent basis during the periods involved, and all adjustments necessary for a fair presentation of results for such periods have been made; all pro forma financial information included in the Registration Statement, the General Disclosure Package and the Prospectus presents fairly in all material respects the information shown therein, has been prepared in accordance with the provisions of the 1933 Act and the 1933 Act Regulations with respect to pro forma financial information, has been properly compiled on the pro forma bases described therein in accordance with the provisions of the 1933 Act and the 1933 Act Regulations, and the assumptions used in the preparation thereof are reasonable and the adjustments therein are appropriate to give effect to the transactions or circumstances referred to therein; the summary and selected combined financial and operating data included in the Registration Statement, the General Disclosure Package and the Prospectus present fairly in all material respects the information shown therein and such data have been compiled on a basis consistent with the financial statements presented therein and the books and records of the Company; there are no financial statements (historical or pro forma) that are required to be included in the Registration Statement, the General Disclosure Package or the Prospectus that are not included as required; the Company and the Subsidiaries do not have any material liabilities or obligations, direct or contingent (including any off-balance sheet obligations), that are not described in the Registration Statement, the General Disclosure Package and the Prospectus; and any disclosures contained in the Registration Statement, the General Disclosure Package and the Prospectus that constitute “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the 1934 Act and Item 10 of Regulation S-K under the 1933 Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.

(xx) Stock Option Grants. Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, each stock option granted under any stock option plan of the Company or any Subsidiary (each, a “Stock Plan”) was granted with a per share exercise price no less than the fair market value per Common Share, or, with respect to incentive stock options granted to an employee who on the date of grant was the owner of stock possessing more than 10% of the total combined voting power of all classes of stock of the Company (after taking into account the attribution of stock ownership rules of Section 424(d) of the Internal Revenue Code of 1986, as amended (the “Code”), no less than 110% of the fair market value per Common Share, on the grant date of such option, as determined by the Company’s board of directors, and no such grant involved any “back-dating,” “forward-dating” or similar practice

 

9


with respect to the effective date of such grant; except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, each such option (i) was granted in compliance with applicable law and with the applicable Stock Plan(s), (ii) was duly approved by the board of directors (or a duly authorized committee thereof or an officer of the Company duly authorized by the board of directors or authorized committee thereof to make such grants) of the Company or such Subsidiary, as applicable, and (iii) has been properly accounted for in the Company’s financial statements in accordance with GAAP.

(xxi) No Material Adverse Change. Except as otherwise set forth or contemplated in, or subsequently incorporated by reference into, the Registration Statement, the General Disclosure Package or the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the General Disclosure Package and the Prospectus, there has not been (i) any material adverse change, or any development involving a prospective material adverse change, in the business, properties, management, financial condition or results of operations of the Company and the Subsidiaries taken as a whole (a “Material Adverse Change”), (ii) any transaction which is material to the Company and the Subsidiaries taken as a whole, (iii) any obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company or any Subsidiary, which is material to the Company and the Subsidiaries taken as a whole, (iv) any change in the capital stock or outstanding indebtedness of the Company or any Subsidiaries, and as described in the Registration Statement, the General Disclosure Package and the Prospectus, the issuance of Common Shares upon exercise of stock options and warrants described as outstanding in the Registration Statement and the Prospectus, the grant in the ordinary course of business of awards under equity incentive plans described in the Registration Statement and the Prospectus and the repurchase by the Company or forfeiture of shares of common stock by the holder thereof pursuant to the terms of equity awards described as outstanding in the Registration Statement and the Prospectus) or (v) any dividend or distribution of any kind declared, paid or made on the capital stock of the Company or any Subsidiary.

(xxii) Investment Company Act. Neither the Company nor any Subsidiary is and, after giving effect to the offering and sale of the Securities, and upon exercise of the Warrants, and the application of the proceeds thereof, neither of the Company nor any Subsidiary will be, an “investment company” or an entity “controlled” by an “investment company,” as such terms are defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”), or a “passive foreign investment company” or a “controlled foreign corporation,” as such terms are defined in the Code.

(xxiii) Real Property. Neither the Company nor the Subsidiaries own any real property; the Company and each of the Subsidiaries have good and marketable title to all tangible personal property described in the Registration Statement, the General Disclosure Package and the Prospectus as being owned by any of them, free and clear of all liens, claims, security interests or other encumbrances, except those that do not materially interfere with the use or proposed use of such property by the Company or the Subsidiary, respectively, or as would not materially or adversely affect the value of such property; all the property described in the Registration Statement, the General Disclosure Package and the Prospectus as being held under lease by the Company or a Subsidiary is held thereby under valid, subsisting and enforceable leases, except where such failure to hold such property would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect and except that the enforcement thereof may be subject to (i) bankruptcy, insolvency, reorganization, receivership, moratorium, fraudulent conveyance or other similar laws relating to creditor’s rights generally and (ii) general principles of equity and the discretion of the court before which any proceeding therefor may be brought.

 

10


(xxiv) Intellectual Property. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and the Subsidiaries own, or have obtained valid and enforceable licenses for, or other rights to use, the patent applications, patents, trademarks, trademark registrations, tradenames, service marks, copyrights, trade secrets and other unpatented or unpatentable proprietary information necessary for, or used in the conduct, or the proposed conduct, of the business of the Company and its Subsidiaries taken as a whole in the manner described in the Registration Statement, the General Disclosure Package and the Prospectus (collectively, “Intellectual Property”), except as such failure to own or obtain rights would not result in a Material Adverse Effect; except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus (i) to the knowledge of the Company, there are no third parties who have any ownership rights in or to any Intellectual Property that is owned by the Company, and, to the knowledge of the Company, no third party has any ownership right in or to any Intellectual Property in any field of use that is exclusively licensed to the Company, other than the licensor to the Company of such Intellectual Property; (ii) the Company has not received written notice of any material infringement by third parties of any Intellectual Property; (iii) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others alleging that the Company is infringing, misappropriating, diluting or otherwise violating any rights of others with respect to any Intellectual Property; (iv) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, enforceability or scope of any of the patent or patent applications owned or exclusively licensed by the Company included in the Intellectual Property; (v) the Company has not received written notice of any claim of material infringement with any asserted rights of others with respect to any of the Company’s products, proposed products, processes or Intellectual Property; (vi) except as would not reasonably be expected to result in a Material Adverse Effect, the development, sale and any currently proposed use of any of the products, proposed products or processes of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus, in the current or proposed conduct of the businesses of the Company in the manner and to the extent described in the Registration Statement and the Prospectus, do not currently, and will not upon commercialization, infringe any right or valid patent claim of any third party; (vii) to the knowledge of the Company, the parties prosecuting the patents and patent applications owned or licensed to the Company or under which the Company has rights included in the Intellectual Property have complied with their duty of candor and disclosure to the U.S. Patent and Trademark Office (the “USPTO”) in connection with such applications and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which would preclude the grant of a patent in connection with any such application, or in the view of the Company could form a reasonable basis of a finding of invalidity with respect to any patents that have issued with respect to such applications; (viii) there is no prior art that may render any patent application within the Intellectual Property unpatentable that has not been disclosed to the U.S. Patent and Trademark Office or of which the Company is otherwise aware; (ix) the product candidates described in the Registration Statement, the General Disclosure Package and the Prospectus as under development by the Company or any Subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company or any Subsidiary; and (x) to the Company’s knowledge, there is no patent or published patent application in the U.S. or other jurisdiction which contains claims that dominate or may dominate the Intellectual Property or that interferes with the issued or pending claims of any such Intellectual Property; the description of the Intellectual Property included or incorporated by reference in the Registration Statement and the Prospectus is accurate and complete in all material respects and presents fairly the information purported to be described therein.

 

11


(xxv) Labor Matters. Except for matters which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, there is (A) no unfair labor practice complaint pending or, to the Company’s knowledge, threatened against the Company or any of the Subsidiaries before the National Labor Relations Board, and no grievance or arbitration proceeding arising out of or under collective bargaining agreements is pending, or to the Company’s knowledge, threatened and (B) no strike, labor dispute, slowdown or stoppage pending or, to the Company’s knowledge, threatened against the Company or any of the Subsidiaries or against any of the principal suppliers, contractors or customers of the Company or any of its Subsidiaries.

(xxvi) Environmental Matters. The Company and the Subsidiaries are in compliance with, and hold all permits, authorizations and approvals required under, Environmental Laws (as defined below), except to the extent that failure to so comply or to hold such permits, authorizations or approvals would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; the Company and the Subsidiaries are not aware of any non-compliance with Environmental Laws, any past or present events, conditions, activities, practices, actions, omissions or plans that could reasonably be expected to result in non-compliance with Environmental Laws or any current liabilities under Environmental Laws, that could individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; the Company and the Subsidiaries (i) are not the subject of any investigation known to the Company, (ii) have not received any notice or claim, (iii) are not a party to any pending or, to the Company’s knowledge, threatened action, suit or proceeding, (iv) are not bound by any judgment, decree or order or (v) have not entered into any agreement, in each case relating to any alleged violation of any Environmental Law or any actual or alleged release or threatened release or cleanup at any location of any Hazardous Materials (as defined below) (as used herein, “Environmental Law” means any federal, state, local or foreign law, statute, ordinance, rule, regulation, order, decree, judgment, injunction, permit, license, authorization or other legal requirement relating to health, safety or the protection, cleanup or restoration of the environment or natural resources, including those relating to the distribution, processing, generation, treatment, storage, disposal, transportation, other handling or release or threatened release of Hazardous Materials, and “Hazardous Materials” means any material (including, without limitation, pollutants, contaminants, hazardous or toxic substances or wastes) that is regulated by or may give rise to liability under any Environmental Law).

(xxvii) Tax Matters. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, all material tax returns required to be filed by the Company or any of the Subsidiaries have been filed (subject to permitted extensions), and all material taxes and other assessments of a similar nature (whether imposed directly or through withholding) including any material interest, additions to tax or penalties applicable thereto due or claimed to be due from such entities have been paid, other than those being contested in good faith and for which adequate reserves have been provided.

(xxviii) Insurance Matters. The Company and each of the Subsidiaries maintain insurance covering their respective properties, operations, personnel and businesses as the Company reasonably deems adequate; such insurance insures against such losses and risks in accordance with customary industry practice to protect the Company and the Subsidiaries and their respective businesses and which is commercially reasonably for the current conduct of their respective businesses; to the Company’s knowledge, all such insurance is fully in force on the date hereof and is expected to be fully in force at each time of purchase, if any; neither the Company nor any Subsidiary has reason to believe that it will not be able to (i) renew any such insurance as and when such insurance expires or (ii) obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted at a cost that would not, individually or in the aggregate, reasonably be expected to result in any Material Adverse Effect.

 

12


(xxix) Termination Notices. Except as referred to or described in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has sent or received any communication regarding termination of, or intent not to renew, any of the contracts or agreements referred to or described in the Registration Statement, the General Disclosure Package or the Prospectus, and no such termination or non-renewal has been threatened by the Company or any Subsidiary or, to the Company’s knowledge, any counterparty to any such contract or agreement.

(xxx) Internal Controls. The Company and the Subsidiaries maintain a system of “internal controls over financial reporting” (as defined in Rule 13a-15(f) of the 1934 Act) that has been designed by, or under the supervision of, the Company’s principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization and any unauthorized access that could have a material effect on the Company’s financial statements is timely detected; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Registration Statement and the Prospectus, there are no material weaknesses in the Company’s internal controls. The auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal controls over financial reporting.

(xxxi) Disclosure Controls. The Company and its Subsidiaries have established and maintain and evaluate “disclosure controls and procedures” (as such term is defined in Rule 13a-15 under the 1934 Act); such disclosure controls and procedures have been designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company’s Chief Executive Officer and its Chief Financial Officer by others within those entities, and such disclosure controls and procedures are effective to perform the functions for which they were established; no “significant deficiencies” or “material weaknesses” (as such terms are defined in Rule 1-02(a)(4) of Regulation S-X under the 1933 Act) of the Company were identified in connection with the audit by the Company’s independent registered public accountants of the Company’s financial statements for the fiscal year ended December 31, 2021; since the date of the most recent evaluation of such disclosure controls and procedures and internal controls, there have been no significant changes in internal controls or in other factors that could significantly affect internal controls, including any corrective actions with regard to significant deficiencies and material weaknesses and the principal executive officer and principal financial officer of the Company have made all certifications required by the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) and any related rules and regulations promulgated by the Commission, and the statements contained in each such certification are complete and correct in all material respects.

(xxxii) Sarbanes-Oxley Compliance. The Company has taken all actions reasonably necessary to ensure that the Company and the Subsidiaries and their respective officers and directors, in their capacities as such, are in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act and the rules and regulations promulgated in connection therewith.

 

13


(xxxiii) Forward-Looking Statements. Each “forward-looking statement” (within the meaning of Section 27A of the 1933 Act or Section 21E of the 1934 Act) contained in the Registration Statement, the General Disclosure Package and the Prospectus has been made or reaffirmed with a reasonable basis and in good faith.

(xxxiv) Statistical and Market-Related Data. All statistical and market-related data included in the Registration Statement, the General Disclosure Package and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate.

(xxxv) FCPA, etc. None of the Company, any of the Subsidiaries or any of their respective officers or directors or, to the knowledge of the Company, any agent, employee or controlled affiliate of the Company or any of the Subsidiaries (i) has, directly or indirectly, made, offered, promised, or authorized the unlawful payment or provision of anything of value to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of any public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office, or (ii) is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder, or the OECD Convention on Bribery of Foreign Public Officials in International Business Transactions; the Company, the Subsidiaries and, to the knowledge of the Company, its controlled affiliates have instituted and maintain policies and procedures designed to ensure continued compliance therewith.

(xxxvi) Money Laundering Laws. The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the USA PATRIOT Act, the Bank Secrecy Act of 1970, as amended, the anti-money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator or non-governmental authority involving the Company or any of the Subsidiaries with respect to the Money Laundering Laws is pending or, to the Company’s knowledge, threatened.

(xxxvii) Sanctions. None of the Company, any of the Subsidiaries or any of their respective officers or directors or, to the knowledge of the Company, any agent, employee or controlled affiliate of the Company or any of the Subsidiaries is currently subject to or has been subject in the last five (5) years to any sanctions administered or enforced by the Office of Foreign Assets Control of the U.S. Treasury Department, the United Nations Security Council, the European Union, Her Majesty’s Treasury or any other relevant sanctions authority (collectively, “Sanctions”), nor is the Company or any of its Subsidiaries organized or resident in a country or territory that is the subject of Sanctions, including, without limitation, Crimea, Cuba, Iran, North Korea, and Syria (each, a “Sanctioned Country”), and the Company will not knowingly directly or indirectly use the proceeds of the offering of the Securities contemplated hereby, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person or country that, at the time of such funding or facilitation, is known to the Company to be the subject of Sanctions or a Sanctioned Country, respectively, or (ii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor, or otherwise) of Sanctions. To best of the Company’s knowledge, for the past five years, none of the Company or any Subsidiaries has engaged in any direct or indirect dealings or transactions with any person or country that, at the time of such dealing or transaction, was the subject of Sanctions or a Sanctioned Country, respectively.

 

14


(xxxviii) Patriot Act. The Company acknowledges that, in accordance with the requirements of the USA PATRIOT Act, the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients.

(xxxix) Transactions with SDN List. To best of the Company’s knowledge, neither the Company nor its Subsidiaries do any business with Russian entities, including any ministry, agency, state-owned entity, or sovereign fund of the Russian Federation (Central Bank of Russia, the National Wealth Fund, the Ministry of Finance of the Russian Federation) or any entity on the Specially Designated Nationals and Blocked Persons List (“SDN List”), the Non-SDN Menu-Based Sanctions List, the Sectoral Sanctions Identifications List, or List of Foreign Financial Institutions Subject to Correspondent Account or Payable-Through Account Sanctions, Office of Financial Sanctions Implementation HM Treasury Consolidated List of Financial Sanctions Targets in the UK or designated under European Union sanctions measures.

(xl) No Dividend Restrictions. No Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such Subsidiary’s capital stock, from repaying to the Company any loans or advances to such Subsidiary from the Company or from transferring any of such Subsidiary’s property or assets to the Company or any other Subsidiary of the Company, except as described in the Registration Statement, the General Disclosure Package and the Prospectus.

(xli) Health Regulatory Compliance. The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company that are described in, or the results of which are referred to in, the Registration Statement, the General Disclosure Package and the Prospectus were and, if still pending, are being conducted in all material respects in accordance with applicable local, state and federal laws, rules and regulations, including, but not limited to, the Federal Food, Drug and Cosmetic Act and its applicable implementing regulations; each description of the results of such studies contained in the Registration Statement, the General Disclosure Package and the Prospectus is accurate in all material respects and fairly presents the data derived from such studies, and the Company is not aware of any other studies the results of which the Company believes reasonably call into question the study results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus; and except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, neither the Company nor any Subsidiary has received any written notices or other written correspondence from the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency having jurisdiction over the Company or any of its properties (collectively, the “Regulatory Agencies”) requiring the termination, suspension or material adverse modification of any clinical trials that are described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus; and the Company and the Subsidiaries have each operated and currently are in compliance with all applicable rules and regulations of the Regulatory Agencies except where the failure to be in compliance would not be expected reasonably to have a Material Adverse Effect.

 

15


(xlii) Compliance with Health Care Laws. The Company and the Subsidiaries are, and since January 1, 2017 have been, in compliance with all applicable Health Care Laws except where failure to be in compliance would not be expected reasonably to have a Material Adverse Effect. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.), and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), the U.S. Civil False Claims Act (31 U.S.C. §§ 3729 et seq.), the Federal False Statements Law (42 U.S.C. § 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. §§ 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. §§ 1320d et seq.), the Civil Monetary Penalties Law (42 U.S.C. § 1320a-7a), the exclusion laws (42 U.S.C. § 1320a-7), the Medicare statute (Title XVIII of the Social Security Act), and the Medicaid statute (Title XIX of the Social Security Act) and the regulations promulgated pursuant to such statutes; (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.), and the regulations promulgated thereunder; (iv) the U.S. Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), and the regulations promulgated thereunder; and (v) any and all other applicable health care laws and regulation applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development by the Company. Neither the Company nor the Subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority alleging that any product operation or activity is in material violation of any Health Care Laws, and, to the Company’s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. Neither the Company nor the Subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, none of the Company or its Subsidiaries or any of their respective officers or directors or, to the Company’s knowledge, any of their respective employees has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. The Company and the Subsidiaries have filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by the Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission), except in each case, as would not reasonably be expected to have a Material Adverse Effect.

(xliii) Cybersecurity and Data Privacy. The Company and the Subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and the Subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all Personal Data (as defined below) that is in the Company’s possession, and sensitive, confidential or

 

16


regulated data (collectively, the “Confidential Data”)) used in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Confidential Data and to the protection of such IT Systems and Confidential Data from unauthorized use, access, misappropriation or modification. “Personal Data” means (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) Protected Health Information as defined by HIPAA; (iv) “personal data” as defined by General Data Protection Regulation, and (v) any other piece of information that allows the identification of such natural person.

(xliv) Brokers. Except pursuant to this Agreement, neither the Company nor any of the Subsidiaries has incurred any liability for any finder’s or broker’s fee or agent’s commission in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby or by the Registration Statement.

(xlv) ERISA Matters. Except for matters which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, each “employee benefit plan” (within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (“ERISA”)) for which the Company or any member of its “Controlled Group” (defined as any organization that is a member of a controlled group of corporations within the meaning of Section 414 of the Code, including its subsidiaries, would have liability (each a “Plan”) is in compliance in all material respects with all presently applicable statutes, rules and regulations, including ERISA and the Code; (ii) with respect to each Plan subject to Title IV of ERISA (a) no “reportable event” (as defined in Section 4043 of ERISA) has occurred for which the Company or any member of its Controlled Group would have any liability; and (b) neither the Company nor any member of its Controlled Group has incurred or expects to incur liability under Title IV of ERISA (other than for contributions to the Plan or premiums payable to the Pension Benefit Guaranty Corporation, in each case in the ordinary course and without default); (iii) no Plan which is subject to Section 412 of the Code or Section 302 of ERISA has failed to satisfy the minimum funding standard within the meaning of such sections of the Code or ERISA; and (iv) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or by failure to act, which would reasonably be expected to cause the loss of such qualification.

(xlvi) Stock Exchange Listing. The Common Shares are registered pursuant to Section 12(b) of the 1934 Act and are listed on the Nasdaq Global Market, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Shares under the 1934 Act or delisting the Common Shares from the Nasdaq Global Market, nor has the Company received any notification that the Commission or the Nasdaq Global Market is contemplating terminating such registration or listing.

 

17


(xlvii) Selecta RUS. Selecta (RUS) Limited Liability Company (i) does not own any Intellectual Property or assets that are material to the Company’s business and (ii) does not have any operations that are material to the Company’s business or prospects.

(xlviii) Timely Filing. The Company has timely made all filings required to be made under the 1934 Act.

Officer’s Certificates. Any certificate signed by any officer of the Company or any of its Subsidiaries delivered to the Representative or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby.

SECTION 2. Sale and Delivery to Underwriters; Closing.

(a) Securities. On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to purchase from the Company, at the price per share set forth in Schedule A, that number of Securities set forth in Schedule A opposite the name of such Underwriter, plus any additional number of Securities which such Underwriter may become obligated to purchase pursuant to the provisions of Section 10 hereof, subject, in each case, to such adjustments among the Underwriters as the Representative in its sole discretion shall make to eliminate any sales or purchases of fractional shares.

(b) Payment. Payment of the purchase price for, and delivery of certificates or security entitlements for, the Securities shall be made at the offices of Goodwin Procter LLP, 620 8th Avenue, New York, New York 10018, or at such other place as shall be agreed upon by the Representative and the Company, at 9:00 A.M. (New York City time) on the second (third, if the pricing occurs after 4:30 P.M. (New York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section 10), or such other time not later than ten business days after such date as shall be agreed upon by the Representative and the Company (such time and date of payment and delivery being herein called “Closing Time”). Delivery of the Securities at the Closing Time shall be made through the facilities of The Depository Trust Company unless the Representative shall otherwise instruct.

Payment shall be made to the Company by wire transfer of immediately available funds to a bank account designated by the Company, against delivery to the Representative for the respective accounts of the Underwriters of certificates or security entitlements for the Securities to be purchased by them. It is understood that each Underwriter has authorized the Representative, for its account, to accept delivery of, receipt for, and make payment of the purchase price for, the Securities which it has agreed to purchase. SVB Securities, individually and not as representative of the Underwriters, may (but shall not be obligated to) make payment of the purchase price for the Securities to be purchased by any Underwriter whose funds have not been received by the Closing Time, but such payment shall not relieve such Underwriter from its obligations hereunder.

SECTION 3. Covenants of the Company. The Company covenants with each Underwriter as follows:

(a) Compliance with Securities Regulations and Commission Requests. The Company, subject to Section 3(b), will comply with the requirements of Rule 430B, and will notify the Representative as soon as practicable, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed, (ii) of the receipt of any comments from the Commission, (iii) of any request by the Commission for any

 

18


amendment to the Registration Statement or any amendment or supplement to the Prospectus (including any document incorporated by reference therein) or for additional information, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any preliminary prospectus or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the 1933 Act concerning the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the 1933 Act in connection with the offering of the Securities. The Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company will make every reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment.

(b) Continued Compliance with Securities Laws. The Company will comply with the 1933 Act, the 1933 Act Regulations, the 1934 Act and the 1934 Act Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the General Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (“Rule 172”), would be) required by the 1933 Act to be delivered in connection with sales of the Securities, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) amend or supplement the General Disclosure Package or the Prospectus in order that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the 1933 Act or the 1933 Act Regulations, the Company will promptly (A) give the Representative notice of such event, (B) prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representative or counsel for the Underwriters shall object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representative notice of any filings made pursuant to the 1934 Act or the 1934 Act Regulations within 48 hours prior to the Applicable Time; the Company will give the Representative notice of its intention to make any such filing from the Applicable Time to the Closing Time and will furnish the Representative with copies of any such documents a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representative or counsel for the Underwriters shall reasonably object.

 

19


(c) Delivery of Registration Statements. The Company has furnished or will deliver to the Representative and counsel for the Underwriters, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith or incorporated by reference therein and documents incorporated or deemed incorporated by reference therein) and signed copies of all consents and certificates of experts, and will also deliver to the Representative, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

(d) Delivery of Prospectuses. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the 1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

(e) Blue Sky Qualifications. The Company will use its best efforts, in cooperation with the Underwriters, to qualify the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representative may designate and to maintain such qualifications in effect so long as required to complete the distribution of the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.

(f) Rule 158. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available to its securityholders as soon as practicable an earning statement for the purposes of, and to provide to the Underwriters the benefits contemplated by, the last paragraph of Section 11(a) of the 1933 Act.

(g) Use of Proceeds. The Company will use the net proceeds received by it from the sale of the Securities in all material respects in the manner specified in the Registration Statement, the General Disclosure Package and the Prospectus under the heading “Use of Proceeds.”

(h) Listing. The Company will use its best efforts to effect and maintain the listing of the Common Stock (including the Securities) on the Nasdaq Global Market.

(i) Restriction on Sale of Securities. During a period of 90 days from the date of the Prospectus, the Company will not, without the prior written consent of the Representative, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file or confidentially submit any registration statement under the 1933 Act with respect to any of the foregoing, (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (iii) publicly announce an intention to effect any such swap, agreement or other transaction described in clauses (i) and (ii). The foregoing sentence shall not apply to (A) the Securities to be sold hereunder; (B) any shares of Common Stock issued by the Company upon the exercise of an option or warrant or the conversion of a convertible security outstanding on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (C) any

 

20


shares of Common Stock issued or options to purchase Common Stock granted pursuant to existing employee benefit plans of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus; (D) any shares of Common Stock issued pursuant to any existing non-employee director stock plan or dividend reinvestment plan referred to in the Registration Statement, the General Disclosure Package and the Prospectus; or (E) the filing by the Company of any registration statement on Form S-8 or a successor form thereto.

(j) Reporting Requirements. The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations. Additionally, the Company shall report the use of proceeds from the issuance of the Securities as may be required under Rule 463 under the 1933 Act.

(k) Issuer Free Writing Prospectuses. The Company agrees that, unless it obtains the prior written consent of the Representative, it will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a “free writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representative will be deemed to have consented to the Issuer Free Writing Prospectuses listed on Schedule B-2 hereto and any “road show that is a written communication” within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representative. The Company represents that it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Representative as an “issuer free writing prospectus,” as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representative and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.

(l) Testing-the-Waters Materials. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representative and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.

SECTION 4. Payment of Expenses.

(a) Expenses. The Company will pay or cause to be paid all reasonable and documented expenses incident to the performance of its obligations under this Agreement, including (i) the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii) the preparation, printing and delivery to the Underwriters of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors, (iii) the preparation, issuance and delivery of the certificates or

 

21


security entitlements for the Securities to the Underwriters, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery of the Securities to the Underwriters, (iv) the fees and disbursements of the Company’s counsel, accountants and other advisors, (v) the qualification of the Securities under securities laws in accordance with the provisions of Section 3(e) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of a “Blue Sky Survey” and any supplement thereto, (vi) the fees and expenses of any transfer agent or registrar for the Securities, (vii) the filing fees incident to, and the reasonable fees and disbursements of counsel to the Underwriters in connection with, the review by FINRA of the terms of the sale of the Securities, in an amount not to exceed $20,000, (viii) the fees and expenses incurred in connection with the listing of the Securities on the Nasdaq Global Market, and (ix) the costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Securities made by the Underwriters caused by a breach of the representation contained in the third sentence of Section 1(a)(ii).

(b) Termination of Agreement. If this Agreement is terminated by the Representative in accordance with the provisions of Section 5, Section 9(a)(i), Section 9(a)(iii) or Section 10 hereof, the Company shall reimburse the Underwriters for all of their reasonably documented out-of-pocket expenses, including the reasonable fees and disbursements of counsel for the Underwriters.

SECTION 5. Conditions of Underwriters’ Obligations. The obligations of the several Underwriters hereunder are subject to the accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company or any of its Subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and other obligations hereunder, and to the following further conditions:

(a) Effectiveness of Registration Statement. The Registration Statement has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company’s knowledge, contemplated; and the Company has complied with each request (if any) from the Commission for additional information to the reasonable satisfaction of counsel to the Underwriters.

(b) Opinion of Counsels for Company. At the Closing Time, the Representative shall have received the opinion and negative assurance letter, dated the Closing Time, of Covington & Burling LLP, counsel for the Company and the opinion of Wolf, Greenfield & Sacks, P.C., special counsel for the Company with respect to intellectual property matters, each in form and substance reasonably satisfactory to counsel for the Underwriters, together with signed or reproduced copies of each such letter for each of the other Underwriters.

(c) Opinion of Counsel for Underwriters. At the Closing Time, the Representative shall have received the opinion, and negative assurance letter, each dated the Closing Time, of Goodwin Procter LLP, counsel for the Underwriters, together with signed or reproduced copies of such letters for each of the other Underwriters in form and substance satisfactory to the Representative. In giving such opinion such counsel may rely, as to all matters governed by the laws of jurisdictions other than the law of the State of New York, the General Corporation Law of the State of Delaware and the federal securities laws of the United States, upon the opinions of counsel satisfactory to the Representative. Such counsel may also state that, insofar as such opinion involves factual matters, they have relied, to the extent they deem proper, upon certificates of officers and other representatives of the Company and its Subsidiaries and certificates of public officials.

 

22


(d) Officers’ Certificate. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, and the Representative shall have received a certificate of the principal executive officer of the Company and of the principal financial officer of the Company, dated the Closing Time, to the effect that (i) there has been no such material adverse change, (ii) the representations and warranties of the Company in this Agreement are true and correct with the same force and effect as though expressly made at and as of the Closing Time, (iii) the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied at or prior to the Closing Time, and (iv) no stop order suspending the effectiveness of the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to their knowledge, contemplated.

(e) Accountant’s Comfort Letter. At the time of the execution of this Agreement, the Representative shall have received from Ernst & Young LLP, a letter, dated such date, in form and substance satisfactory to the Representative, together with signed or reproduced copies of such letter for each of the other Underwriters containing statements and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in the Registration Statement, the General Disclosure Package and the Prospectus.

(f) Bring-down Comfort Letter. At the Closing Time, the Representative shall have received from Ernst & Young LLP, a letter, dated as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (e) of this Section, except that the specified date referred to shall be a date not more than three business days prior to the Closing Time.

(g) Approval of Listing. At the Closing Time, the Securities and the Warrant Shares shall have been approved for listing on the Nasdaq Global Select Market, subject only to official notice of issuance.

(h) No Objection. FINRA has confirmed that it has not raised any objection with respect to the fairness and reasonableness of the underwriting terms and arrangements relating to the offering of the Securities.

(i) Lock-up Agreements. At the date of this Agreement, the Representative shall have received an agreement substantially in the form of Exhibit A hereto signed by all of the Company’s directors and officers.

(j) Debt Securities. Neither the Company nor its subsidiaries have outstanding any debt securities or preferred stock that are rated by any “nationally recognized statistical rating agency” (as defined in Section 3(a)(62) of the 1934 Act).

(k) Additional Documents. At the Closing Time, counsel for the Underwriters shall have been furnished with such other documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be reasonably satisfactory in form and substance to the Representative and counsel for the Underwriters.

 

23


(l) Termination of Agreement. If any condition specified in this Section shall not have been fulfilled when and as required to be fulfilled, this Agreement may be terminated by the Representative by notice to the Company at any time at or prior to Closing Time, and such termination shall be without liability of any party to any other party except as provided in Section 4 and except that Sections 1, 4, 6, 7, 8, 14, 15 and 16 shall survive any such termination and remain in full force and effect.

SECTION 6. Indemnification.

(a) Indemnification of Underwriters. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term is defined in Rule 501(b) under the 1933 Act (each, an “Affiliate”)), its selling agents and each person, if any, who controls any Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act as follows:

(i) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included (A) in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto), or (B) in any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities (“Marketing Materials”), including any roadshow or investor presentations made to investors by the Company (whether in person or electronically), or the omission or alleged omission in any preliminary prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication, the General Disclosure Package, the Prospectus (or any amendment or supplement thereto) or in any Marketing Materials of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;

(ii) against any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to Section 6(d) below) any such settlement is effected with the written consent of the Company;

(iii) against any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the Representative), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;

provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.

 

24


(b) Indemnification of Company, Directors and Officers. Each Underwriter severally agrees to indemnify and hold harmless the Company, its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act, against any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a) of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including any information deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.

(c) Actions against Parties; Notification. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. In the case of parties indemnified pursuant to Section 6(a) above, counsel to the indemnified parties shall be selected by the Representative, and, in the case of parties indemnified pursuant to Section 6(b) above, counsel to the indemnified parties shall be selected by the Company. An indemnifying party may participate at its own expense in the defense of any such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. In no event shall the indemnifying parties be liable for the reasonable fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 6 or Section 7 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.

(d) Settlement without Consent if Failure to Reimburse. If at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section 6(a)(ii) effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.

SECTION 7. Contribution. If the indemnification provided for in Section 6 hereof is for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and of the Underwriters, on the other hand, in connection with the statements or omissions, which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations.

 

25


The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate offering price of the Securities as set forth on the cover of the Prospectus.

The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section 7. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 7 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission.

Notwithstanding the provisions of this Section 7, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Securities underwritten by it and distributed to the public.

No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

For purposes of this Section 7, each person, if any, who controls an Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and each Underwriter’s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as the Company. The Underwriters’ respective obligations to contribute pursuant to this Section 7 are several in proportion to the number of Securities set forth opposite their respective names in Schedule A hereto and not joint.

SECTION 8. Representations, Warranties and Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company or any of its Subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company and (ii) delivery of and payment for the Securities.

 

26


SECTION 9. Termination of Agreement.

(a) Termination. The Representative may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing Time (i) if there has been, in the judgment of the Representative, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, or (ii) if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving a prospective change in U.S. or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representative, impracticable or inadvisable to proceed with the completion of the offering or to enforce contracts for the sale of the Securities, or (iii) if trading in any securities of the Company has been suspended or materially limited by the Commission or the Nasdaq Global Market, or (iv) if trading generally on the NYSE MKT or the New York Stock Exchange or in the Nasdaq Global Market has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the Commission, FINRA or any other governmental authority, or (v) a material disruption has occurred in commercial banking or securities settlement or clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi) if a banking moratorium has been declared by either Federal or New York authorities.

(b) Liabilities. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to any other party except as provided in Section 4 hereof, and provided further that Sections 1, 4, 6, 7, 8, 15, 16 and 17 shall survive such termination and remain in full force and effect.

SECTION 10. Default by One or More of the Underwriters. If one or more of the Underwriters shall fail at the Closing Time to purchase the Securities which it or they are obligated to purchase under this Agreement (the “Defaulted Securities”), the Representative shall have the right, within 24 hours thereafter, to make arrangements for one or more of the non-defaulting Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein set forth; if, however, the Representative shall not have completed such arrangements within such 24-hour period, then:

(i) if the number of Defaulted Securities does not exceed 10% of the number of Securities to be purchased on such date, each of the non-defaulting Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective underwriting obligations hereunder bear to the underwriting obligations of all non-defaulting Underwriters, or

(ii) if the number of Defaulted Securities exceeds 10% of the number of Securities to be purchased on such date, this Agreement shall terminate without liability on the part of any non-defaulting Underwriter.

No action taken pursuant to this Section shall relieve any defaulting Underwriter from liability in respect of its default.

 

27


In the event of any such default which does not result in a termination of this Agreement, either the (i) Representative or (ii) the Company shall have the right to postpone Closing Time for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General Disclosure Package or the Prospectus or in any other documents or arrangements. As used herein, the term “Underwriter” includes any person substituted for an Underwriter under this Section 10.

SECTION 11. Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to SVB Securities at 1301 Avenue of the Americas, 12th Floor, New York, New York, 10019, attention of Stuart R. Nayman.

SECTION 12. No Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (a) the purchase and sale of the Securities pursuant to this Agreement, including the determination of the offering price of the Securities and any related discounts and commissions, is an arm’s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b) in connection with the offering of the Securities and the process leading thereto, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, any of its Subsidiaries or their respective stockholders, creditors, employees or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering of the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company or any of its Subsidiaries on other matters) and no Underwriter has any obligation to the Company with respect to the offering of the Securities except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company and (e) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and the Company has consulted its own respective legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.

SECTION 13. Recognition of the U.S. Special Resolution Regimes. In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.

In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

For purposes of this Agreement, (A) “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k); (B) “Covered Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b); (C) “Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable; and (D) “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

 

28


SECTION 14. Parties. This Agreement shall each inure to the benefit of and be binding upon the Underwriters and the Company and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Underwriters and the Company and their respective successors and the controlling persons and officers and directors referred to in Sections 6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase.

SECTION 15. Waiver of Trial by Jury. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

SECTION 16. GOVERNING LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.

SECTION 17. Consent to Jurisdiction; Waiver of Immunity. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby shall be instituted in (i) the federal courts of the United States of America located in the City and County of New York, Borough of Manhattan or (ii) the courts of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.

SECTION 18. TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.

SECTION 19. Partial Unenforceability. The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.

SECTION 20. Counterparts. This Agreement may be executed in any number of counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

29


SECTION 21. Effect of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof.

SECTION 22. Entire Agreement. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof.

[SIGNATURE PAGES FOLLOW]

 

 

30


If the foregoing is in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Underwriters and the Company in accordance with its terms.

 

Very truly yours,
SELECTA BIOSCIENCES, INC.
By:  

/s/ Carsten Brunn, Ph.D.

  Name: Carsten Brunn, Ph.D.
  Title: President and Chief Executive Officer

 

CONFIRMED AND ACCEPTED
  As of the date first above written:
SVB SECURITIES LLC
By:  

/s/ Dan Dubin

  Name: Dan Dubin
  Title: Vice Chairman

For itself and as Representative of the other Underwriters named in Schedule A hereto.

[SIGNATURE PAGE TO UNDERWRITING AGREEMENT]


SCHEDULE A

The combined offering price shall be $1.41 per Share and accompanying Warrant.

The combined purchase price per Share and Warrant to be paid by the several Underwriters shall be $1.3254, being an amount equal to the offering price set forth above less $0.0846 per Share and accompanying Warrant.

 

Name of Underwriter

   Number of
Shares
     Number of
Warrants
 

SVB Securities LLC

     21,942,858        16,457,144  

Canaccord Genuity LLC

     5,485,714        4,114,285  
  

 

 

    

 

 

 

Total

     27,428,572        20,571,429  
  

 

 

    

 

 

 


SCHEDULE B-1

Pricing Terms

1. The Company is selling 27,428,572 shares of Common Stock and warrants to purchase 20,571,429 shares of Common Stock.

2. The combined offering price per share for the Common Stock and warrant shall be $1.41.


SCHEDULE B-2

Free Writing Prospectuses

None


SCHEDULE B-3

List of Written Testing-the-Waters Communications

None


Exhibit A

Form of Lock-Up Agreement

April ___, 2022

SVB Securities LLC

as Representative of the several Underwriters

c/o SVB Securities LLC

53 State Street, 40th Floor

Boston, MA 02109

 

Re:

Proposed Public Offering by Selecta Biosciences, Inc.

Ladies and Gentlemen:

The undersigned, an officer and/or director of Selecta Biosciences, Inc., a Delaware corporation (the “Company”), understands that SVB Securities LLC (“SVB Securities”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with the Company providing for the public offering (the “Public Offering”) of shares (the “Securities”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). In recognition of the benefit that such an offering will confer upon the undersigned as an officer and/or a director of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting Agreement (collectively, the “Underwriters”) that, during the period beginning on the date hereof and ending on the date that is 90 days from the date of the Underwriting Agreement (the “Lock-Up Period”), the undersigned will not, without the prior written consent of SVB Securities, on behalf of the Underwriters, directly or indirectly, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer any shares of Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the “Lock-Up Securities”), or exercise any right with respect to the registration of any of the Lock-Up Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act of 1933, as amended, or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of Common Stock or other securities, in cash or otherwise.

Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent of SVB Securities, provided, in each case, that (1) in the cases of (i), (ii), (iii), (iv) and (x) below, SVB Securities receives a signed lock-up agreement for the balance of the Lock-Up Period from each donee, trustee, distributee, or transferee, as the case may be, (2) any such transfer shall not involve a disposition for value, (3) in the cases of (i) – (iv) below, such transfers are not required to be reported with the Securities and Exchange Commission on Form 4 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and (4) the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers (other than a filing on a Form 5 made after the expiration of the Lock-Up Period):

 


  (i)

as a bona fide gift or gifts or for bona fide estate planning purposes;

 

  (ii)

to any member of the immediate family of the undersigned or any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this lock-up agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin);

 

  (iii)

as a distribution or other transfer by a partnership to its partners or former partners or by a limited liability company to its members or retired members or by a corporation to its stockholders or former stockholders or to any wholly-owned subsidiary of such corporation;

 

  (iv)

to the undersigned’s affiliates or to any investment fund or other entity controlled or managed by the undersigned;

 

  (v)

pursuant to a qualified domestic relations order or in connection with a divorce settlement;

 

  (vi)

by will, other testamentary document or intestate succession upon the death of the undersigned;

 

  (vii)

to the Company, or the withholding of shares of Common Stock by the Company, upon the vesting or exercise of an option or other award granted under an equity incentive plan or stock purchase plan of the Company described in the prospectus supplement relating to the Public Offering (the “Prospectus”) or the conversion or exercise of a convertible security or warrant of the Company described in the Prospectus (in each case, by way of “net” exercise in accordance with their terms, and/or to cover withholding tax obligations in connection with such exercise), provided that any such shares of Common Stock received upon such vesting, exercise or conversion shall be subject to the terms of this agreement and if the undersigned is required to make a filing under the Exchange Act reporting a reduction in beneficial ownership of shares of Common Stock during the Lock-Up Period, the undersigned shall include a statement in such report to the effect that the purpose of such transfer was in connection with a “net exercise” or to cover tax obligations of the undersigned, as applicable, in connection with such transfer;

 

  (viii)

to the Company pursuant to any contractual arrangement in effect on the date of the Prospectus that provides for the repurchase of the undersigned’s Common Stock or such other securities by the Company or in connection with the termination of the undersigned’s services to with the Company, provided that the only filings under Section 16(a) that may be made during the Lock-Up Period in connection with any such transfers or dispositions are any Forms 4 or Forms 5 required to be filed under the Exchange Act if the undersigned is subject to Section 16 reporting with respect to the Company under the Exchange Act, and such Form 4 or 5 includes footnote disclosure or otherwise states the nature of the transfer or disposition;

 

  (ix)

in connection with the conversion of any convertible security into, or the exercise of any option or warrant for, shares of Common Stock in a manner consistent with the description of such securities contained in the Prospectus, provided that any such shares of Common Stock received shall be subject to the terms of this agreement;

 

  (x)

to a charitable organization or educational institution;

 

2


  (xi)

to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (x) above;

 

  (xii)

by operation of law, including pursuant to orders of a court or regulatory agency, a domestic order or negotiated divorce settlement; provided that the only filings under Section 16(a) that may be made during the Lock-Up Period in connection with any such transfers or dispositions are any Forms 4 or Forms 5 required to be filed under the Exchange Act if the undersigned is subject to Section 16 reporting with respect to the Company under the Exchange Act, and such Form 4 or 5 includes footnote disclosure or otherwise states the nature of the transfer or disposition; or

 

  (xiii)

pursuant to a bona fide third-party tender offer for all outstanding shares of the Company, merger, consolidation or other similar transaction made to all holders of the Company’s securities involving a change of control of the Company (including, without limitation, the entering into of any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of shares of Common Stock or other such securities in connection with such transaction, or vote any shares of Common Stock or other securities in favor of any such transaction), provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall remain subject to the provisions of this agreement.

Notwithstanding anything herein to the contrary, nothing herein shall prevent the undersigned from establishing a 10b5-1 trading plan that complies with Rule 10b5-1 under the Exchange Act (“10b5-1 Trading Plan”) or from amending an existing 10b5-1 Trading Plan so long as there are no sales of Lock-Up Securities under any such 10b5-1 Trading Plan during the Lock-Up Period; and provided that, the establishment of a 10b5-1 Trading Plan or the amendment of a 10b5-1 Trading Plan shall only be permitted if (i) the establishment or amendment of such plan is not required to be reported in any public report or filing with the Securities Exchange Commission, or otherwise, and (ii) the undersigned does not otherwise voluntarily effect any public filing or report regarding the establishment or amendment of such plan.

The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the Lock-Up Securities except in compliance with the foregoing restrictions. This lock-up agreement shall automatically terminate, and the undersigned shall be released from the undersigned’s obligations hereunder, upon the earliest to occur, if any, of (i) prior to the execution of the Underwriting Agreement, the Company advises SVB Securities in writing that it has determined not to proceed with the Public Offering; (ii) the Underwriting Agreement is executed but is terminated prior to the closing of the Public Offering (other than the provisions thereof which survive termination), or (iii) April 29, 2022, in the event that the Underwriting Agreement has not been executed by such date.

This agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

This agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

[SIGNATURE PAGE FOLLOWS]

 

3


Very truly yours,

 

Name of Security Holder (Print exact name)
By:  

 

  Signature
If not signing in an individual capacity:

 

Name of Authorized Signatory (Print)

 

Title of Authorized Signatory (Print)

(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)

 

4

EX-4.1 3 d535347dex41.htm EX-4.1 EX-4.1

Exhibit 4.1

COMMON STOCK PURCHASE WARRANT

SELECTA BIOSCIENCES, INC.

 

Warrant Shares: _______

   Issue Date: April 11, 2022

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and on or prior to 5:00 p.m. (New York City time) on April 11, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Selecta Biosciences, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement (the “Underwriting Agreement”), dated April 6, 2022, between the Company and SVB Securities LLC, as representative of the underwriters named therein.

Section 2. Exercise.

a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Issue Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) business day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

b) Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $[ ], subject to adjustment hereunder (the “Exercise Price”).

c) Cashless Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

  (A) =

as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP


  on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;

 

  (B) =

the Exercise Price of this Warrant, as adjusted hereunder; and

 

  (X) =

the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c).

Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the OTCQB or the OTCQX (or any successors to any of the foregoing).

VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.


d) Mechanics of Exercise.

i. Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

iii. Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2)


the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

v. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

vii. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other common stock equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or


Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. Notwithstanding the foregoing, the Beneficial Ownership Limitation described in this Section 2(e) shall not apply to TAS Partners LLC or any of its Affiliates or Attribution Parties.

Section 3. Certain Adjustments.

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.


b) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any common stock equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

c) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

d) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the outstanding voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the outstanding voting power of the common equity of the Company (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)


receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. Notwithstanding the foregoing, in the event of a Change of Control, that is approved by the Company’s Board of Directors (and not for avoidance of doubt if the Change of Control is not within the Company’s control), the Holder shall be entitled to receive from the Company or any Successor Entity, as of the date of consummation of such Change of Control, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Change of Control, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Change of Control. As used herein, “Black Scholes Value” means the value of this Warrant based on the Black- Scholes Option Pricing Model obtained from the “OV” function on Bloomberg determined as of the day immediately following the first public announcement of the applicable Change of Control, or, if the Change of Control is not publicly announced, the date the Change of Control is consummated, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of tins Warrant as of such date of request, (ii) an expected volatility equal to the lesser of (x) 100% and (y) the 30 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Change of Control, (iii) the underlying price per share used in such calculation shall be the greater of (a) the highest Weighted Average Price during the five (5) Trading Days prior to the closing of the Change of Control and (b) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Change of Control, (iv) a zero cost of borrow and (v) a 360 day annualization factor. As used herein, “Change of Control” means any Fundamental Transaction other than (i) any reorganization, recapitalization or reclassification of the Common Stock in which holders of the Company’s voting power immediately prior to such reorganization, recapitalization or reclassification continue after such reorganization, recapitalization or reclassification to hold publicly traded securities and, directly or indirectly, are, in all material respect, the holders of the voting power of the surviving entity (or entities with the authority or voting power to elect the members of the board


of directors (or their equivalent if other than a corporation) of such entity or entities) after such reorganization, recapitalization or reclassification, (ii) pursuant to a migratory merger effected solely for the purpose of changing the jurisdiction of incorporation of the Company or (iii) a merger in connection with a bona fide acquisition by the Company of any Person in which (x) the gross consideration paid, directly or indirectly, by the Company in such acquisition is not greater than 20% of the Company’s market capitalization as calculated on the date of the consummation of such merger and (y) such merger does not contemplate a change to the identity of a majority of the board of directors of the Company. Notwithstanding anything herein to the contrary, any transaction or series of transaction that, directly or indirectly, results in the Company or the Successor Entity not having Common Stock or common stock, as applicable, registered under the 1934 Act and listed on an Eligible Market shall be deemed a Change of Control. As used herein, “Eligible Market” means The Nasdaq Capital Market, the NYSE American LLC, The Nasdaq Global Select Market, The Nasdaq Global Market or The New York Stock Exchange, Inc.

e) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

f) Voluntary Adjustment By Company. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.

g) Notice to Holder.

i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (and all of its Subsidiaries, taken as a whole) is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.


Section 4. Transfer of Warrant.

a) Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

b) New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

Section 5. Miscellaneous.

a) No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.

b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.

d) Authorized Shares.


The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Underwriting Agreement.

f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

h) Notices. Any notices, consents, waivers or other document or communications required or permitted to be given or delivered under the terms of this Warrant must be in writing and will be deemed to have been delivered: (i) upon receipt, if delivered personally; (ii) when sent, if sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); (iii) when sent, if sent by e-mail (provided that such sent e-mail is kept on file (whether electronically or otherwise) by the sending party and the sending party does not receive an automatically generated message from the recipient’s e-mail server that such e-mail could not be delivered to such recipient) and (iv) if sent


by overnight courier service, one (1) Trading Day after deposit with an overnight courier service with next day delivery specified, in each case, properly addressed to the party to receive the same. If notice is given by facsimile or email, a copy of such notice shall be dispatched no later than the next business day by first class mail, postage prepaid. The addresses, facsimile numbers and e-mail addresses for such communications shall be:

If to the Company:

Selecta Biosciences, Inc.

65 Grove Street

Watertown, MA 02472

Attention: Kevin Tan

    Chief Financial Officer

    Email: [***]

With a copy (for informational purposes only) to:

Covington & Burling LLP

The New York Times Building

620 Eighth Avenue

New York, NY 10018

Attention: Brian Rosenzweig

Email: brosenzweig@cov.com

If to a Holder, to its address, facsimile number or e-mail address set forth herein or on the books and records of the Company.

Or, in each of the above instances, to such other address, facsimile number or e-mail address and/or to the attention of such other Person as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the sender’s facsimile machine containing the time, date and recipient facsimile number or (C) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iv) above, respectively. A copy of the e-mail transmission containing the time, date and recipient e- mail address shall be rebuttable evidence of receipt by e-mail in accordance with clause (iii) above.

i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.


m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

SELECTA BIOSCIENCES, INC.
By:  

 

  Name: Kevin Tan
  Title: Chief Financial Officer


NOTICE OF EXERCISE

 

TO:    Selecta Biosciences, Inc.

(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

(2) Payment shall take the form of (check applicable box):

[ ] in lawful money of the United States; or

[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

                                                         

The Warrant Shares shall be delivered to the following DWAC Account Number:

                                                         

                                                         

                                                         

[SIGNATURE OF HOLDER]

 

Name of Investing Entity:
Signature of Authorized Signatory of Investing Entity:
Name of Authorized Signatory:
Title of Authorized Signatory:
Date:


ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

Name:     

 

     (Please Print)
Address:     

 

     (Please Print)
Phone Number:     
Email Address:     

 

Dated: _______________ __, ______     

 

 

Holder’s Signature:

 

Holder’s Address:

EX-5.1 4 d535347dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

 

LOGO

   LOGO

April 7, 2022

Selecta Biosciences, Inc.

65 Grove Street

Watertown, Massachusetts 02472

Ladies and Gentlemen:

We have acted as counsel to Selecta Biosciences, Inc., a Delaware corporation (the “Company”), in connection with the issuance and sale on the date hereof by the Company of 27,428,572 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants to purchase 20,571,429 shares of Common Stock (the “Warrants,” and, together with the Shares, the “Securities”), pursuant to the Underwriting Agreement, dated April 6, 2022, by and between the Company, on the one hand, and SVB Securities LLC, as representative of the several underwriters named therein (the “Underwriters”), on the other (the “Underwriting Agreement”). The offer and sale of the Securities are being registered under the Securities Act pursuant to the Company’s registration statement on Form S-3 (File No. 333-241692), which was filed with the Securities and Exchange Commission on August 6, 2020 (such registration statement, as amended as of the date hereof, is herein referred to as the “Registration Statement”).

We have reviewed the Underwriting Agreement, the Registration Statement, and the prospectus, dated August 14, 2020, as supplemented by a prospectus supplement with respect to the offer and sale of the Securities, as filed with the Securities and Exchange Commission on April 6, 2022. We have also reviewed such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purposes of this opinion.

We have assumed that all signatures are genuine, that all documents submitted to us as originals are authentic and that all copies of documents submitted to us conform to the originals.

We have relied as to certain matters on information obtained from public officials, officers of the Company and other sources believed by us to be responsible.

Based upon the foregoing, we are of the opinion that (i) the Warrants have been duly executed, and when sold and delivered in accordance with their terms and upon receipt by the Company of the consideration specified therein, any Warrant Shares issuable upon exercise of Warrants will be validly issued, fully paid and non-assessable, (ii) when the Warrants have been duly executed and delivered in accordance with the terms of the Underwriting Agreement and have been duly issued and sold as contemplated in the Registration Statement, the Warrants will constitute the valid and binding obligations of the Company, enforceable against the Company in


LOGO

Selecta Biosciences, Inc.

April 7, 2022

Page 2

 

accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other laws of general applicability relating to or affecting creditors’ rights and to general equity principles and (iii) the Shares have been duly authorized, and when issued and sold by the Company pursuant to the terms of the Underwriting Agreement and upon receipt by the Company of full payment therefor in accordance with the Underwriting Agreement, will be validly issued, fully paid and non-assessable.

We express no opinion as to: (i) waivers of defenses, subrogation and related rights, rights to trial by jury, rights to object to venue, or other rights or benefits bestowed by operation of law; (ii) releases or waivers of unmatured claims or rights; (iii) indemnification, contribution, exculpation, or arbitration provisions, or provisions for the non-survival of representations, to the extent they purport to indemnify any party against, or release or limit any party’s liability for, its own breach or failure to comply with statutory obligations, or to the extent such provisions are contrary to public policy; or (iv) provisions for liquidated damages and penalties, penalty interest and interest on interest.

We are members of the bar of the State of New York. We do not express any opinion herein on any laws other than the law of the State of New York, the Delaware General Corporation Law, applicable provisions of the Delaware Constitution and reported judicial decisions interpreting these laws.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Company’s Current Report on Form 8-K dated the date hereof related to the offering of the Securities. We also hereby consent to the reference to our firm under the heading “Legal Matters” in the prospectus supplement constituting part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

 

Very truly yours,
/s/ Covington & Burling LLP
EX-99.1 5 d535347dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Selecta Biosciences Announces $38.7 Million Underwritten Offering

WATERTOWN, Mass., April 6, 2022 – Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta” or the “Company”), a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune responses, today announced that it has agreed to sell 27,428,572 shares of its common stock and accompanying warrants to purchase up to 20,571,429 shares of common stock at a combined offering price of $1.41 per share and accompanying warrant. The warrants to purchase shares of common stock have an exercise price of $1.55 per share, are immediately exercisable and will expire five years from the date of issuance. All of the securities in the offering will be sold by Selecta. The gross proceeds to Selecta from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $38.7 million. The offering is expected to close on April 11, 2022, subject to the satisfaction of customary closing conditions.

SVB Leerink is acting as sole bookrunning manager for the offering. Canaccord Genuity is acting as lead manager for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-241692) that was previously filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2020 and declared effective on August 14, 2020. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. When available, copies of the final prospectus supplement and accompanying prospectus may also be obtained by contacting SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbleerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of Selecta’s securities, nor shall there be any sale of Selecta’s securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Selecta Biosciences, Inc.

Selecta Biosciences, Inc. is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the completion and anticipated proceeds of the proposed offering. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to fluctuations in Selecta’s stock price, changes in market conditions and satisfaction of customary closing conditions related to the offering, as well as the other factors discussed in the “Risk Factors” section in Selecta’s most recently filed Annual Report on Form 10-K as well as other risks detailed in Selecta’s subsequent filings with the Securities and Exchange Commission. There can be no assurance that Selecta will be able to complete the proposed offering on the anticipated terms. All information in this press release is as of the date of the release, and Selecta undertakes no duty to update this information unless required by law.


For Investors:

Bruce Mackle

LifeSci Advisors, LLC

Phone: +1-929-469-3859

Email: bmackle@lifesciadvisors.com

For Media:

Brittany Leigh, Ph.D.

LifeSci Communications, LLC

Phone: +1-646-751-4366

Email: bleigh@lifescicomms.com

EX-101.SCH 6 selb-20220406.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 7 selb-20220406_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 8 selb-20220406_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 9 g535347dsp01a.jpg GRAPHIC begin 644 g535347dsp01a.jpg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end GRAPHIC 10 g535347dsp02.jpg GRAPHIC begin 644 g535347dsp02.jpg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end GRAPHIC 11 g535347g0406202417504.jpg GRAPHIC begin 644 g535347g0406202417504.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 06, 2022
Cover [Abstract]  
Entity Registrant Name SELECTA BIOSCIENCES INC
Amendment Flag false
Entity Central Index Key 0001453687
Document Type 8-K
Document Period End Date Apr. 06, 2022
Entity Incorporation State Country Code DE
Entity File Number 001-37798
Entity Tax Identification Number 26-1622110
Entity Address, Address Line One 65 Grove Street
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 923-1400
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol SELB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 13 d535347d8k_htm.xml IDEA: XBRL DOCUMENT 0001453687 2022-04-06 2022-04-06 SELECTA BIOSCIENCES INC false 0001453687 8-K 2022-04-06 DE 001-37798 26-1622110 65 Grove Street Watertown MA 02472 (617) 923-1400 false false false false Common Stock, $0.0001 par value per share SELB NASDAQ false EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 15 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d535347d8k.htm d535347dex11.htm d535347dex41.htm d535347dex51.htm d535347dex991.htm selb-20220406.xsd selb-20220406_lab.xml selb-20220406_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 20 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d535347d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d535347d8k.htm" ] }, "labelLink": { "local": [ "selb-20220406_lab.xml" ] }, "presentationLink": { "local": [ "selb-20220406_pre.xml" ] }, "schema": { "local": [ "selb-20220406.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "selb", "nsuri": "http://www.selectabio.com/20220406", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d535347d8k.htm", "contextRef": "duration_2022-04-06_to_2022-04-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d535347d8k.htm", "contextRef": "duration_2022-04-06_to_2022-04-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com//20220406/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 21 0001193125-22-098074-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-098074-xbrl.zip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�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